


ELX-02 disulfate

Chemical Properties

CAS No. :	2244622-33-9
Formula:	C19H40N4O14S
Molecular Weight:	580.6
Storage:	Keep away from direct sunlight Powder: -20°C for 3 years In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



Biological Description

Description	ELX-02 disulfate is a synthetic eukaryotic ribosome-specific glycoside (ERSG) that induces translation read-through of nonsense mutations, producing normally localized, full-length functional proteins. It can be used to study genetic diseases caused by nonsense mutations.
Targets(IC50)	Others
In vitro	ELX-02 disulfate (10/30 mg/kg; subcutaneous injection; twice weekly for 8 doses) accumulates in tissues in a dose-dependent manner [1]. ELX-02 disulfate administered at 10 mg/kg subcutaneously, both as a single dose and repeatedly (twice weekly for 7 doses), is rapidly absorbed into plasma. The plasma half-life of ELX-02 disulfate is 0.5 hours [1]. In CtnsY226X nonsense mutation mice, ELX-02 disulfate accumulates in renal tissue without apparent nephrotoxicity. Treatment with ELX-02 disulfate (10 mg/kg; twice weekly; for 3 weeks) reduced renal cystine accumulation in vivo [1].
In vivo	ELX-02 disulfate (100-400 µg/mL) can read through nonsense mutations in human cells [1].

Solubility Information

Solubility	DMSO: < 1 mg/mL (insoluble) H2O: 80 mg/mL (137.79 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.7224 mL	8.6118 mL	17.2236 mL
5 mM	0.3445 mL	1.7224 mL	3.4447 mL
10 mM	0.1722 mL	0.8612 mL	1.7224 mL
50 mM	0.0344 mL	0.1722 mL	0.3445 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Leubitz A, et al. Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX-02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers. Clin Pharmacol Drug Dev. 2019;8(8):984-994.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481